[
  {
    "ts": "2026-01-09T09:00:00+00:00",
    "headline": "Bull of the Day: Eli Lilly (LLY)",
    "summary": "Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.",
    "url": "https://finance.yahoo.com/news/bull-day-eli-lilly-lly-090000015.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "466dad8b-f70b-355d-a1f2-27465d2b7109",
      "content": {
        "id": "466dad8b-f70b-355d-a1f2-27465d2b7109",
        "contentType": "STORY",
        "title": "Bull of the Day: Eli Lilly (LLY)",
        "description": "",
        "summary": "Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.",
        "pubDate": "2026-01-09T09:00:00Z",
        "displayTime": "2026-01-09T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/34e9e082846727ec8f9de30166d4e01c",
          "originalWidth": 620,
          "originalHeight": 300,
          "caption": "Zacks Investment Research",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/snPNf0X6c7oh8neoGyOvQQ--~B/aD0zMDA7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/34e9e082846727ec8f9de30166d4e01c.cf.webp",
              "width": 620,
              "height": 300,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BDWlpByoSGsIyaG28LOn9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/34e9e082846727ec8f9de30166d4e01c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bull-day-eli-lilly-lly-090000015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bull-day-eli-lilly-lly-090000015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "INCY"
            },
            {
              "symbol": "RHHBF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:03:45+00:00",
    "headline": "Schrodinger to offer Eli Lilly's AI drug discovery platform on its software",
    "summary": "By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.",
    "url": "https://finance.yahoo.com/news/schrodinger-offer-eli-lillys-ai-120345241.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "060520a4-1d56-3754-8bce-293dd39e1a45",
      "content": {
        "id": "060520a4-1d56-3754-8bce-293dd39e1a45",
        "contentType": "STORY",
        "title": "Schrodinger to offer Eli Lilly's AI drug discovery platform on its software",
        "description": "",
        "summary": "By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.",
        "pubDate": "2026-01-09T12:03:45Z",
        "displayTime": "2026-01-09T12:03:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/f25a0702086183bacd7b8a1425d8e069",
          "originalWidth": 800,
          "originalHeight": 534,
          "caption": "FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.BsEyKXgL0C_78ZqRtxegQ--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f25a0702086183bacd7b8a1425d8e069.cf.webp",
              "width": 800,
              "height": 534,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GEhaigdd0AGTEFmsRHeIHQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/f25a0702086183bacd7b8a1425d8e069.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/schrodinger-offer-eli-lillys-ai-120345241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/schrodinger-offer-eli-lillys-ai-120345241.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:00:00+00:00",
    "headline": "Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign",
    "summary": "NEW YORK, January 09, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.",
    "url": "https://finance.yahoo.com/news/schr-dinger-partners-lilly-tunelab-120000797.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a140161a-0389-3466-b66f-b72e99a1bbf3",
      "content": {
        "id": "a140161a-0389-3466-b66f-b72e99a1bbf3",
        "contentType": "STORY",
        "title": "Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign",
        "description": "",
        "summary": "NEW YORK, January 09, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.",
        "pubDate": "2026-01-09T12:00:00Z",
        "displayTime": "2026-01-09T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/265dd09e6c994bd31c4ce58ff55d9e1a",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ulaQbaET.rVrDLn9Rzys_g--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/265dd09e6c994bd31c4ce58ff55d9e1a.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OPjeWDdPBAlw2_jlPQvstA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/265dd09e6c994bd31c4ce58ff55d9e1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/schr-dinger-partners-lilly-tunelab-120000797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/schr-dinger-partners-lilly-tunelab-120000797.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "SDGR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T09:45:00+00:00",
    "headline": "Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day",
    "summary": "Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.",
    "url": "https://finance.yahoo.com/news/eli-lilly-jd-com-highlighted-094500680.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "eb1e4ca3-cc85-3bc1-ba31-6403f741b331",
      "content": {
        "id": "eb1e4ca3-cc85-3bc1-ba31-6403f741b331",
        "contentType": "STORY",
        "title": "Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day",
        "description": "",
        "summary": "Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.",
        "pubDate": "2026-01-09T09:45:00Z",
        "displayTime": "2026-01-09T09:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-jd-com-highlighted-094500680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-jd-com-highlighted-094500680.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "JD"
            },
            {
              "symbol": "BBAI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T13:00:43+00:00",
    "headline": "Demand For Google, Palantir Is Mere Peanuts Next To These 3 Stocks",
    "summary": "While AI stocks Google, Broadcom and Palantir remain in demand, the best mutual funds shoveled massive sums into 3 stocks.",
    "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-funds-buy-google-broadcom-palantir-but-place-massive-bets-here/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "5671a2a6-3e87-3485-a124-b18fd9494254",
      "content": {
        "id": "5671a2a6-3e87-3485-a124-b18fd9494254",
        "contentType": "STORY",
        "title": "Demand For Google, Palantir Is Mere Peanuts Next To These 3 Stocks",
        "description": "",
        "summary": "While AI stocks Google, Broadcom and Palantir remain in demand, the best mutual funds shoveled massive sums into 3 stocks.",
        "pubDate": "2026-01-09T13:00:43Z",
        "displayTime": "2026-01-09T13:00:43Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/5671a2a6-3e87-3485-a124-b18fd9494254/demand-for-google-palantir.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a69c2df9a4dcdcc84afcfbf2f71fc70d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ydJQdAJgsCJcEKf8G_YUyw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a69c2df9a4dcdcc84afcfbf2f71fc70d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3gwaIitLsG3NkheXkN1Jzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a69c2df9a4dcdcc84afcfbf2f71fc70d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/etfs-and-funds/mutual-funds/best-mutual-funds-buy-google-broadcom-palantir-but-place-massive-bets-here/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "SAN"
            },
            {
              "symbol": "PLUS"
            },
            {
              "symbol": "AIR"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "AVGO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "GE"
            },
            {
              "symbol": "ASML"
            },
            {
              "symbol": "LRCX"
            },
            {
              "symbol": "RIO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T13:00:00+00:00",
    "headline": "Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models",
    "summary": "WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.",
    "url": "https://finance.yahoo.com/news/revvity-collaborates-lilly-expand-access-130000963.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a2d177a0-e1b1-3ffb-9dfd-e5e5d9ddfbb7",
      "content": {
        "id": "a2d177a0-e1b1-3ffb-9dfd-e5e5d9ddfbb7",
        "contentType": "STORY",
        "title": "Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models",
        "description": "",
        "summary": "WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.",
        "pubDate": "2026-01-09T13:00:00Z",
        "displayTime": "2026-01-09T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629",
          "originalWidth": 784,
          "originalHeight": 320,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VIAQmKPhUw0Tb0iso8v4nQ--~B/aD0zMjA7dz03ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629.cf.webp",
              "width": 784,
              "height": 320,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3Pv.KuW5Yu2ZKaJQlz5Jjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revvity-collaborates-lilly-expand-access-130000963.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revvity-collaborates-lilly-expand-access-130000963.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RVTY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T14:00:00+00:00",
    "headline": "Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery",
    "summary": "SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.",
    "url": "https://finance.yahoo.com/news/chai-discovery-announces-collaboration-eli-140000319.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "f514887b-31e7-363e-b053-6636454019cd",
      "content": {
        "id": "f514887b-31e7-363e-b053-6636454019cd",
        "contentType": "STORY",
        "title": "Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery",
        "description": "",
        "summary": "SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.",
        "pubDate": "2026-01-09T14:00:00Z",
        "displayTime": "2026-01-09T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jUqEofigJX6d12_WipofRw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BEMpypfUX6hkd3.nTOzXKA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a75bf0b588e00f006480d6e3efda88d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chai-discovery-announces-collaboration-eli-140000319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chai-discovery-announces-collaboration-eli-140000319.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T12:44:00+00:00",
    "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
    "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
    "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "56543896-1532-3429-ae94-e3a17404ce99",
      "content": {
        "id": "56543896-1532-3429-ae94-e3a17404ce99",
        "contentType": "STORY",
        "title": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
        "description": "",
        "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
        "pubDate": "2026-01-09T12:44:00Z",
        "displayTime": "2026-01-09T12:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-expect-abbvies-immunology-segment-124400845.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T15:54:33+00:00",
    "headline": "Here’s What UBS Thinks About Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment […]",
    "url": "https://finance.yahoo.com/news/ubs-thinks-eli-lilly-company-155433063.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c2c9ef1c-04c6-3900-9df0-83b7ee5401bf",
      "content": {
        "id": "c2c9ef1c-04c6-3900-9df0-83b7ee5401bf",
        "contentType": "STORY",
        "title": "Here’s What UBS Thinks About Eli Lilly and Company (LLY)",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment […]",
        "pubDate": "2026-01-09T15:54:33Z",
        "displayTime": "2026-01-09T15:54:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7SniT2cAwGKi0gxMU3rg8Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OYjuUHa2wfRuGI22z0Csjw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ubs-thinks-eli-lilly-company-155433063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ubs-thinks-eli-lilly-company-155433063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UBS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T14:58:00+00:00",
    "headline": "VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug",
    "summary": "Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.",
    "url": "https://finance.yahoo.com/news/vktx-completes-enrollment-phase-maintenance-145800404.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "bcde9e51-4ea0-3846-bf29-87773c1048e3",
      "content": {
        "id": "bcde9e51-4ea0-3846-bf29-87773c1048e3",
        "contentType": "STORY",
        "title": "VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug",
        "description": "",
        "summary": "Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.",
        "pubDate": "2026-01-09T14:58:00Z",
        "displayTime": "2026-01-09T14:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vktx-completes-enrollment-phase-maintenance-145800404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vktx-completes-enrollment-phase-maintenance-145800404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T14:50:00+00:00",
    "headline": "Amazon Pharmacy Begins Offering Wegovy Pill",
    "summary": "Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month.",
    "url": "https://www.wsj.com/health/pharma/amazon-pharmacy-begins-offering-wegovy-pill-ad779583?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "dc1fb4ac-01f1-3f2a-a770-5d876e4b4374",
      "content": {
        "id": "dc1fb4ac-01f1-3f2a-a770-5d876e4b4374",
        "contentType": "STORY",
        "title": "Amazon Pharmacy Begins Offering Wegovy Pill",
        "description": "",
        "summary": "Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month.",
        "pubDate": "2026-01-09T14:50:00Z",
        "displayTime": "2026-01-09T14:50:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/dc1fb4ac-01f1-3f2a-a770-5d876e4b4374/amazon-pharmacy-begins.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/441188501e5c1a09c92a689e879eda6e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zdJpV7SwosU4AEZ1NVxcmg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/441188501e5c1a09c92a689e879eda6e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFxQ7ocbnRbLqIFn_GM9Kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/441188501e5c1a09c92a689e879eda6e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/amazon-pharmacy-begins-offering-wegovy-pill-ad779583?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "COST"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T11:28:00+00:00",
    "headline": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
    "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
    "url": "https://www.biopharmadive.com/news/johnson-price-insmed-moonlake-madrigal-pfizer-lexeo-lilly/809169/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "671bb6d5-1cc6-3099-b8ce-812e3302ebb5",
      "content": {
        "id": "671bb6d5-1cc6-3099-b8ce-812e3302ebb5",
        "contentType": "STORY",
        "title": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
        "description": "",
        "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
        "pubDate": "2026-01-09T11:28:00Z",
        "displayTime": "2026-01-09T11:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/johnson-price-insmed-moonlake-madrigal-pfizer-lexeo-lilly/809169/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/insmed-ginormous-lung-drug-sales-112800003.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "INSM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "MLTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "LXEO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T16:19:02+00:00",
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "03266a6e-1b9f-3ef6-8e9d-12bbed252141",
      "content": {
        "id": "03266a6e-1b9f-3ef6-8e9d-12bbed252141",
        "contentType": "STORY",
        "title": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
        "description": "",
        "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
        "pubDate": "2026-01-09T16:19:02Z",
        "displayTime": "2026-01-09T16:19:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786",
          "originalWidth": 800,
          "originalHeight": 475,
          "caption": "FILE PHOTO: Safeway pharmacist Ronak Amin is shown at is work station at the store in Wheaton, Maryland February 13, 2015.    REUTERS/Gary Cameron   (UNITED STATES)/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ESs_JVgpUQvUr8Q6yFeQ3Q--~B/aD00NzU7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786.cf.webp",
              "width": 800,
              "height": 475,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GQSAeWySZoA3xd2AMPsRVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/753b31989bb885c77e11b66781eb9786.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/healthcare-dealmakers-head-san-francisco-161902747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "INSM"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "GPCR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T15:51:00+00:00",
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d39c6485-53a9-3f97-8b62-0c5a45561ba8",
      "content": {
        "id": "d39c6485-53a9-3f97-8b62-0c5a45561ba8",
        "contentType": "STORY",
        "title": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
        "description": "",
        "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
        "pubDate": "2026-01-09T15:51:00Z",
        "displayTime": "2026-01-09T15:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tugIemz.T.iquqxVIoxpHw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SHyaOdZAc4DXCya2O4.DtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/74bab520128f201c7e6cc3f67385e761.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-strikes-drug-pricing-155100851.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MKGAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T18:36:05+00:00",
    "headline": "Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study",
    "summary": "These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.",
    "url": "https://www.clinicaltrialsarena.com/news/eli-lilly-taltz-zepbound-combination-bests-taltz-psoriatic-arthritis-phase-iiib/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "61dadb84-a8d3-3902-a447-9d79a9db7c38",
      "content": {
        "id": "61dadb84-a8d3-3902-a447-9d79a9db7c38",
        "contentType": "STORY",
        "title": "Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study",
        "description": "",
        "summary": "These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.",
        "pubDate": "2026-01-09T18:36:05Z",
        "displayTime": "2026-01-09T18:36:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/2b3ed96273de6ecd6840686fcbaed166",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "A combination of Eli Lilly's IL-17 inhibitor Taltz and its weight loss therapy",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/drb.Y5dy9pP.mM0EvNThfw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/2b3ed96273de6ecd6840686fcbaed166.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0FmhNXLcwUUPOYV1yZ7LVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/2b3ed96273de6ecd6840686fcbaed166.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/eli-lilly-taltz-zepbound-combination-bests-taltz-psoriatic-arthritis-phase-iiib/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-taltz-zepbound-combo-183605390.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T18:24:59+00:00",
    "headline": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
    "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
    "url": "https://finance.yahoo.com/news/aktis-oncology-jumps-27-318-182459997.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "2da3f4d6-a9f3-3b81-a08e-42663a2ba454",
      "content": {
        "id": "2da3f4d6-a9f3-3b81-a08e-42663a2ba454",
        "contentType": "STORY",
        "title": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
        "description": "",
        "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
        "pubDate": "2026-01-09T18:24:59Z",
        "displayTime": "2026-01-09T18:24:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/aktis-oncology-jumps-27-318-182459997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/aktis-oncology-jumps-27-318-182459997.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MDT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T17:58:00+00:00",
    "headline": "Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets",
    "summary": "LOS ANGELES & BOSTON, January 09, 2026--Vida Ventures (\"Vida\"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co",
    "url": "https://finance.yahoo.com/news/vida-ventures-congratulates-aktis-oncology-175800601.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "cd740407-f74d-34d2-aad3-a156b265ded9",
      "content": {
        "id": "cd740407-f74d-34d2-aad3-a156b265ded9",
        "contentType": "STORY",
        "title": "Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets",
        "description": "",
        "summary": "LOS ANGELES & BOSTON, January 09, 2026--Vida Ventures (\"Vida\"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co",
        "pubDate": "2026-01-09T17:58:00Z",
        "displayTime": "2026-01-09T17:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/2eab891678cf08bdada478812e794fe1",
          "originalWidth": 1687,
          "originalHeight": 585,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tnFIKv.jx200lyGVc1jTGw--~B/aD01ODU7dz0xNjg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2eab891678cf08bdada478812e794fe1.cf.webp",
              "width": 1687,
              "height": 585,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i5vpGIF2y3oTt1vZP_U5Gg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2eab891678cf08bdada478812e794fe1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vida-ventures-congratulates-aktis-oncology-175800601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vida-ventures-congratulates-aktis-oncology-175800601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T17:20:29+00:00",
    "headline": "Stock Market Rallies Broadly To Highs; Nvidia, AMD, Bloom Energy In Focus: Weekly Review",
    "summary": "The Dow Jones, S&P 500 and Russell 2000 all hit highs on the stock market this week. Nvidia and AMD fell despite unveiling new AI chips at CES.",
    "url": "https://www.investors.com/news/stock-market-rallies-highs-nvidia-amd-bloom-energy/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "173a0eac-7583-3e2c-96aa-54c77b8d5f5b",
      "content": {
        "id": "173a0eac-7583-3e2c-96aa-54c77b8d5f5b",
        "contentType": "STORY",
        "title": "Stock Market Rallies Broadly To Highs; Nvidia, AMD, Bloom Energy In Focus: Weekly Review",
        "description": "",
        "summary": "The Dow Jones, S&P 500 and Russell 2000 all hit highs on the stock market this week. Nvidia and AMD fell despite unveiling new AI chips at CES.",
        "pubDate": "2026-01-09T17:20:29Z",
        "displayTime": "2026-01-09T17:20:29Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/173a0eac-7583-3e2c-96aa-54c77b8d5f5b/stock-market-rallies-broadly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/bf012397578831a262fee2360df31c19",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l5AO.Zvsmktyw7fbKTD3Ow--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/bf012397578831a262fee2360df31c19.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PZqsLojgxbAKrpEqfOX2gg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/bf012397578831a262fee2360df31c19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/stock-market-rallies-highs-nvidia-amd-bloom-energy/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "BE"
            },
            {
              "symbol": "OKLO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-09T16:40:00+00:00",
    "headline": "Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond",
    "summary": "After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.",
    "url": "https://finance.yahoo.com/news/betting-boom-3-healthcare-etfs-164000679.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "9a22af82-f95b-374e-824d-ac5fe5d6c4ba",
      "content": {
        "id": "9a22af82-f95b-374e-824d-ac5fe5d6c4ba",
        "contentType": "STORY",
        "title": "Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond",
        "description": "",
        "summary": "After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.",
        "pubDate": "2026-01-09T16:40:00Z",
        "displayTime": "2026-01-09T16:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b66321e586fa6fdc44309f696ff0a17a",
          "originalWidth": 620,
          "originalHeight": 349,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qZ7PYDACxedFU3SgcOrizA--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b66321e586fa6fdc44309f696ff0a17a.cf.webp",
              "width": 620,
              "height": 349,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jyop59ej5Tytfk_vNceYrw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b66321e586fa6fdc44309f696ff0a17a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/betting-boom-3-healthcare-etfs-164000679.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/betting-boom-3-healthcare-etfs-164000679.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XLV"
            },
            {
              "symbol": "VHCIX"
            },
            {
              "symbol": "VHT"
            },
            {
              "symbol": "IXJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BLK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]